Literature DB >> 3607745

Chemical and biological characterization of 4'-iodo-4'-deoxydoxorubicin.

B Barbieri, F C Giuliani, T Bordoni, A M Casazza, C Geroni, O Bellini, A Suarato, B Gioia, S Penco, F Arcamone.   

Abstract

4'-Iodo-4'-deoxydoxorubicin is a doxorubicin (DXR) analogue with greater lipophilicity and reduced basicity of the amino group. In vitro 4'-iodo-4'-deoxydoxorubicin is more cytotoxic than DXR against a panel of human and murine cell lines and is characterized by a higher and faster uptake. In vivo, the spectrum of activity of 4'-iodo-4'-deoxydoxorubicin is comparable to that of DXR, but the new compound has higher activity against murine P388 leukemia resistant to DXR and against pulmonary metastases from Lewis lung carcinoma. Moreover, the new analogue exhibits antitumor activity also after p.o. administration and shows no cardiotoxicity in experimental systems.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3607745

Source DB:  PubMed          Journal:  Cancer Res        ISSN： 0008-5472            Impact factor:   12.701


  16 in total

1.  Pharmacokinetics and metabolism of iodo-doxorubicin and doxorubicin in humans.

Authors:  K Mross; U Mayer; K Hamm; K Burk; D K Hossfeld
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

2.  The molecular interaction of 4'-iodo-4'-deoxydoxorubicin with Leu-55Pro transthyretin 'amyloid-like' oligomer leading to disaggregation.

Authors:  M P Sebastião; G Merlini; M J Saraiva; A M Damas
Journal:  Biochem J       Date:  2000-10-01       Impact factor: 3.857

3.  Evaluation of cardiotoxicity of a new anthracycline derivative: 4'-deoxy-4'-iodo-doxorubicin.

Authors:  F Villani; M Galimberti; E Lanza; A Rozza; L Favalli; P Poggi
Journal:  Invest New Drugs       Date:  1988-09       Impact factor: 3.850

4.  In vitro activity of 4'-iodo-4'-deoxydoxorubicin on human colo-rectal cancer as measured by a short-term antimetabolic assay.

Authors:  R Villa; N Zaffaroni; F Giuliani; G Colella; O Sanfilippo; R Silvestrini
Journal:  Invest New Drugs       Date:  1990-05       Impact factor: 3.850

5.  Cardiac toxicity and antitumor activity of 4'-deoxy-4'-iodo-doxorubicinol.

Authors:  R Danesi; A Marchetti; N Bernardini; R V La Rocca; G Bevilacqua; M Del Tacca
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

6.  Interaction of the anthracycline 4'-iodo-4'-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis.

Authors:  G Merlini; E Ascari; N Amboldi; V Bellotti; E Arbustini; V Perfetti; M Ferrari; I Zorzoli; M G Marinone; P Garini
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

7.  Cellular pharmacology of the partially non-cross-resistant anthracycline annamycin entrapped in liposomes in KB and KB-V1 cells.

Authors:  R Perez-Soler; Y H Ling; Y Zou; W Priebe
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

8.  Phase II study of 4'-iodo-4'-deoxydoxorubicin in non-resectable non-small-cell lung cancer.

Authors:  J B Sørensen; L Stenbygaard; L Drivsholm; P Dombernowsky; H H Hansen
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

9.  Use of human neuroblastoma continuous cell lines for in vitro drug sensitivity screening.

Authors:  B T Hill; R D Whelan; L K Hosking
Journal:  Invest New Drugs       Date:  1988-04       Impact factor: 3.850

10.  The peculiar binding properties of 4'-deoxy,4'-iododoxorubicin to isolated DNA and 175 bp nucleosomes.

Authors:  C Cera; M Palumbo
Journal:  Nucleic Acids Res       Date:  1991-10-25       Impact factor: 16.971
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.